Clinicians map next-line EGFR lung cancer treatments using NGS, radiation, chemo, amivantamab and ADCs

Clinicians treating non‑small cell lung cancer with EGFR mutations must adapt when tumors become resistant to first‑line therapies. The latest guidance highlights the use of next‑generation sequencing to pinpoint the genetic changes driving resistance.

Based on sequencing results, physicians can select from several options. Radiation and chemotherapy remain standard tools, while newer agents such as the bispecific antibody amivantamab are being incorporated for patients with specific resistance mechanisms.

Antibody‑drug conjugates (ADCs) also feature as a tailored approach, delivering cytotoxic payloads directly to cancer cells identified by molecular profiling. This multi‑modal strategy aims to extend disease control by matching the next line of therapy to the tumor’s evolving biology.

Overall, the emphasis is on a personalized sequence of treatments that leverages both established and emerging modalities to manage EGFR‑driven lung cancer after resistance develops.